To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A)

Inclusion Criteria: * Males and females aged 16 years or older on the day of the first vaccination * No history of hepatitis A or having hepatitis A vaccination * Provided consent to the participation in the study voluntarily after receiving explanations about the objective, method, effect, etc. of this clinical study * Determined by the investigator to be able to be followed up during the study period Exclusion Criteria: * A positive result (Anti-HAV 20 IU/L or above) in an hepatitis A antibody test at the time of screening * Positive hepatitis type B antigen at the time of screening * The following blood test results at the time of screening * ALT: More than 1.5 times the upper limit of normal * AST: More than 1.5 times the upper limit of normal * Total bilirubin: More than 1.5 times the upper limit of normal * Tympanic temperature of 38°C or above within 48 hours prior to the vaccination or on the day of vaccination * Moderate to severe acute or chronic infectious disease on the day of vaccination * History of sensitivity to the following drugs: neomycin, formaldehyde, gentamicin sulfate, any preventive vaccines * Congenital or acquired immunodeficient disease, or receiving immunosuppressive therapy * Received immunosuppressive dose of systemic corticosteroids therapy within 12weeks days before vaccination * uncontrolled epilepsy or neurological disorders * Administered with other vaccine within 4 weeks prior to the screening * Planned with other vaccine within 4 weeks after the vaccination date * Used immunoglobulin formulation or human plasma, or received a transfusion within 12 weeks prior to the screening * Participated in another clinical study within 12 weeks prior to the screening, or currently participating * Pregnant women or breast-feeding women * Other reasons not specified above that, in the opinion of the principal investigator, may make the subject ineligible to participate in the study